Untitled

Alberico L. Catapano

Professor of Pharmacology and Director of the Center of Epidemiology and Preventive Pharmacology at the University of Milan

Alberico L. Catapano is Full Professor of Pharmacology and Director of the Center of Epidemiology and Preventive Pharmacology at the University of Milan, Director of the Laboratory of Lipoproteins, Immunity and Atherosclerosis and the Center for the Study of Atherosclerosis at Bassini Hospital, and the atherosclerosis lipid clinic and genetics at IRCCS at Multimedica, Milan, Italy.

His main research interests include the study of atherosclerosis, lipids, lipoproteins and genetic dyslipidaemias, and he has made landmark observations regarding heat shock proteins and pentraxins in atherogenesis, on high-density lipoproteins in the modulation of the immune response, and on the identification of possible therapeutic targets by exploiting genetic information.
A past President of the European Atherosclerosis Society (EAS), Professor Catapano is currently Chairman of the EAS/European Society of Cardiology (ESC) guidelines for the treatment of dyslipoproteinaemias, President of the Italian Society of Clinical and Experimental Therapy, and a board member of the Italian Society for the Study of Atherosclerosis (SISA), as well as the General Director of the SISA Foundation, Co-editor of Atherosclerosis and Associate Editor of other scientific journals, he has authored more than 550 scientific papers in peer-reviewed journals including the The New England Journal of Medicine, The Lancet, Science, JACC, European Heart Journal, and Nature Reviews Cardiology.

He has been awarded the title of Commendatore della Repubblica for scientific merits in 2021 and is among the highly cited scientists according to Clarivate for 2019 and 2020. His H index is 104 according to Google Scholar.

Contributions

New perspectives of lipid-lowering therapiesWebinars on-demand Efficacy and safety of the oral PCSK9 macrocyclic peptide inhibitor MK-0616: a phase 2b randomized controlled trial91th EAS Congress 2023Late Breaker - Clinical Panel Discussion: How can we reduce cardiovascular risk targeting inflammation via IL-6_91th EAS Congress 2023How can we reduce cardiovascular risk targeting inflammation via IL-6_Inflammatory risk in cardiovascular disease: What do we know?91th EAS Congress 2023How can we reduce cardiovascular risk targeting inflammation via IL-6_Panel Discussion: From combination therapies to discharge strategies. Practical approaches to meet LDL-C goals in ACS91th EAS Congress 2023From combination therapies to discharge strategies. Practical approaches to meet LDL-C goals in ACS Rebuttals: Is there a role for diet and nutrition in LDL lowering?91th EAS Congress 2023Is there a role for diet and nutrition in LDL lowering?A deep dive into CLEAR OUTCOMES and its implicationsWebinars on-demand LCN Lp(a) webinar series #5: Round table with the experts – How to use L(a) in practice, from the point of view of the cardiologist, the lipidologist, the diabetologist and the patientWebinars on-demand LCN Lp(a) webinar series #4: Therapeutic approaches - where we stand today and a look to the futureWebinars on-demand EAS Advanced Course – Rare Lipid Disorders - France & SwitzerlandWebinars on-demand LCN Lp(a) webinar series #3: Recommendations for Lp(a) screeningWebinars on-demand EAS Advanced Course – Rare Lipid Disorders - from LisbonWebinars on-demand Industry Special Lecture - Discussion and Q&AIndustry Special Lecture90th EAS Congress 2022 Lp(a): What we need to knowIndustry Special Lecture90th EAS Congress 2022 IME Session - Should public health recommendations target Lp(a) measurements? - Discussion and Q&AIME Session - Should public health recommendations target Lp(a) measurements?90th EAS Congress 2022 Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention - Discussion and Q&A90th EAS Congress 2022ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia Omega 3 fatty acids in cardiovascular prevention - Where do we stand? - Discussion and Q&A90th EAS Congress 2022Omega 3 fatty acids in cardiovascular prevention - Where do we stand?Implementation of the 2019 lipid guidelines-where are we now? - Discussion and Q&A90th EAS Congress 2022Implementation of the 2019 lipid guidelines-where are we now?Current available therapies - EzetimbeIntro to Clinical Lipidology Bempedoic acid - Mechanism of actionIntro to Clinical Lipidology PCSK9 Inhibition - HIGHLIGHTS FROM RECENT PUBLICATIONSEAS AC in Lipidology Lipid guidelines, where we stand?EAS AC in Lipidology Introduction to the courseEAS AC in Lipidology Closing remarksEAS AC in Lipidology Training Agenda OverviewAn Introduction to Clinical Lipidology The new guidelines for dyslipidaemiaAn Introduction to Clinical Lipidology Guidelines - the goals why?An Introduction to Clinical Lipidology Bempedoic Acid - Mechanism of actionAn Introduction to Clinical Lipidology Will aggressive LDL reduction prevent atherosclerosis?86th EAS Congress 2018 The multifaceted aspects of CV prevention - from nutrition to therapy - Chair86th EAS Congress 2018 Summary and introduction of guidelines85th EAS Congress 2017 New recommendations and concepts in the new guidelines2019 ESC-EAS Dyslipidaemia Guidelines A deep dive into EAS-ESC guidelines for dyslipidaemias Therapeutic Approaches - The EAS way